8-K: FOXO Tech Acquires Vector BioSource; Contingent Stock, Warrants

FOXO Technologies Inc. has entered into a definitive agreement to acquire Vector BioSource Inc. for a combination of cash, preferred stock, warrants, and contingent preferred stock.

Summary

• FOXO Technologies Inc. (the Company) has entered into a Stock Purchase Agreement (SPA) to acquire Vector BioSource Inc. (Vector) through its wholly-owned subsidiary, FOXO Acquisition Corporation.
• The acquisition consideration includes $500,000 in cash, 60,000 shares of FOXO's Series E Cumulative Redeemable Secured Preferred Stock, and three-year warrants to purchase up to $2,000,000 of FOXO's Class A Common Stock.
• An additional 80,000 shares of Series E Preferred Stock are contingent upon Vector achieving at least $4,000,000 in Qualifying Revenue during the 12-month period between the first and second anniversary of the closing date.
• The contingent Series E Preferred Stock will be reduced if Qualifying Revenues are less than $4,000,000, with a reduction of one share for each $25 below the target.
• All 80,000 contingent shares will be issued immediately if a Change of Control of FOXO occurs prior to the two-year anniversary of the closing.
• The closing of the SPA is subject to several conditions, including completion of due diligence, finalization of warrant terms and employment agreements with Vector's sellers, agreement on a 12-month post-closing budget, and funding of up to $1.2 million for Vector's cash requirements.

Sentiment

Score: 6

Explanation: The acquisition represents a strategic expansion for FOXO Technologies, which is generally positive. However, the complex consideration structure, including contingent stock and warrants, along with the significant funding requirement for the acquired entity, introduces elements of uncertainty and potential future dilution, tempering the overall positive sentiment.

Positives

• Strategic acquisition of Vector BioSource Inc. could expand FOXO Technologies' business capabilities and market reach.
• The contingent nature of a portion of the Series E Preferred Stock aligns seller incentives with future revenue performance of the acquired business.

Negatives

• The acquisition involves a complex consideration structure, including cash, preferred stock, warrants, and contingent preferred stock, which could lead to future dilution for existing shareholders.
• FOXO Technologies is required to fund up to $1.2 million for Vector's cash requirements post-closing, representing a significant cash outflow.
• The contingent payment mechanism introduces uncertainty regarding the final number of Series E Preferred Stock shares to be issued.

Risks

• Failure to complete due diligence to FOXO's satisfaction could prevent the closing of the acquisition.
• Inability to finalize warrant terms and employment agreements with Vector's sellers could delay or prevent the closing.
• Disagreement on the 12-month budget for Vector post-closing could hinder the acquisition process.
• Failure to secure or provide the $1.2 million funding for Vector's cash requirements could jeopardize the acquisition or its successful integration.
• Vector may not achieve the $4,000,000 Qualifying Revenue target, impacting the full issuance of contingent Series E Preferred Stock and potentially indicating underperformance of the acquired business.

Future Outlook

The future outlook for FOXO Technologies includes the integration of Vector BioSource and the potential for revenue growth from the acquired business. The issuance of 80,000 additional Series E Preferred Stock shares is contingent on Vector achieving $4,000,000 in Qualifying Revenue within a specific two-year post-closing period, indicating a performance-based component to the acquisition's full cost.

Industry Context

This acquisition reflects a trend of companies in the technology and life sciences sectors seeking to expand their capabilities through strategic mergers and acquisitions. Such deals often aim to integrate complementary technologies or market access, though they frequently involve complex financial structures to manage risk and align incentives.

Stakeholder Impact

• Shareholders of FOXO Technologies Inc. may experience dilution from the issuance of Series E Preferred Stock and warrants as part of the acquisition consideration.
• Shareholders could benefit from potential future revenue growth and strategic expansion resulting from the acquisition of Vector BioSource Inc.
• Vector BioSource Inc.'s employees (who are also sellers) will enter into employment agreements with FOXO Technologies Inc., ensuring continuity and integration.

Next Steps

• Completion of due diligence by FOXO Technologies Inc.
• Finalization of warrant terms and employment agreements with Vector BioSource Inc.'s sellers.
• Agreement on a 12-month budget for Vector BioSource Inc. following the closing.
• Funding of up to $1.2 million for Vector BioSource Inc.'s cash requirements.
• Closing of the Stock Purchase Agreement.

Key Dates

Keywords

Acquisition, Stock Purchase Agreement, Vector BioSource, FOXO Technologies, Series E Preferred Stock, Warrants, Contingent Consideration, Mergers and Acquisitions, Biotech, Corporate Governance